Sequence: FCIGRLCG
| Experiment Id | EXP001846 |
|---|---|
| Paper | Development of an Efficient Transdermal Delivery System of Small Interfering RNA Using Functional Pe |
| Peptide | AT1002 analog (AT-1002) |
| Delivery Success Class | no |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | AT1002 400 µg per application (25 µL) |
| Rna Concentration | 5 µg fluorescent siRNA per application; 10 h |
| Mixing Ratio | siRNA + AT1002 (siRNA 5 µg + AT1002 400 µg) mixed (no N/P) |
| Formulation Format | Topical siRNA + AT1002 (tight junction modulator) for transdermal delivery |
| Formulation Components | FAMsiRNA or Cy3-siGL3 mixed with AT1002 and applied topically to tape-stripped mouse skin |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | ICR mice (male, 6-week); back skin tape-stripped; topical 10 h |
| Administration Route | Topical application to tape-stripped dorsal skin (25 µL); confocal imaging |
| Output Type | In vivo uptake/distribution in skin (confocal microscopy) |
| Output Value | AT1002 drives more uniform surface distribution and deeper signal up to ~20 µm depth vs Tat alone |
| Output Units | |
| Output Notes | AT1002 disrupts ZO-1 staining (tight junction modulation) and effect is reversible after washing. |
| Toxicity Notes | |
| Curation Notes |